Supervised strength training (group 1) for Osteoporosis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Waterloo, Waterloo, Canada
Osteoporosis+2 More
Supervised strength training (group 1) - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Osteoporosis is a bone disease that can result in fractures, disability and an increased risk of premature death. Exercise is recommended for fall and fracture prevention, but health care professionals often recommend walking or lower intensity community exercise classes, which may not be effective for building bone. Further, individuals with osteoporosis are often told to avoid lifting or moving in certain ways, which creates fear and activity avoidance. Conversely, research suggests that to stimulate bone, you need higher loads on bone, with either higher intensity resistance training or impact exercise - the types of things people with low bone mass are told to avoid. Our study will examine different types of exercise intensity and how they translate to building bone in people with low bone mineral density (BMD).

Eligible Conditions

  • Osteopenia (Disorder)
  • Osteoporosis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 30 Secondary · Reporting Duration: Baseline, 6 months and 12 months

Baseline and 12 months
Appendicular lean mass
Bone-free lean mass
Femoral Neck BMD
Height
Hip Geometry
Lumbar Spine BMD
Occiput-to-wall distance
Total Hip BMD
Trabecular Bone Score
Baseline and 6 months
Glucose concentration
Insulin concentration
Markers of bone metabolism
Myokines
Oxidative stress markers/antioxidant status (including oxygen radical absorbance capacity (ORAC) assay, protein carbonyls, glutathione peroxidase activity, thyroredoxin, malondialdehyde)
Pro/anti-inflammatory markers (including TNFalpha, IL-6, IL-10, IL-15)
Month 12
Body weight
Month 12
10 Metre Walk Test.
30 Second Chair Stand Test.
6 Minute Walk Test.
Dietary Intake
EQ5D5L
Four Square Step Test
Grip Strength
Health Service Use
Knee extension peak torque
QUALEFFO-41
Ratio of costs to QALY
Willingness to pay
Over 12 months
Fractures
Non-serious adverse events
Number of people who experience one or more falls
Rate of falls per person per year
Serious adverse events

Trial Safety

Safety Progress

1 of 3

Trial Design

3 Treatment Groups

Home exercise
1 of 3
Supervised strength training (group 1)
1 of 3
Supervised strength training (group 2)
1 of 3
Active Control
Experimental Treatment

324 Total Participants · 3 Treatment Groups

Primary Treatment: Supervised strength training (group 1) · No Placebo Group · N/A

Supervised strength training (group 1)
Other
Experimental Group · 1 Intervention: Supervised strength training (group 1) · Intervention Types: Other
Supervised strength training (group 2)
Other
Experimental Group · 1 Intervention: Supervised strength training (group 2) · Intervention Types: Other
Home exercise
Other
ActiveComparator Group · 1 Intervention: Home exercise · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 6 months and 12 months
Closest Location: University of Waterloo · Waterloo, Canada
2009First Recorded Clinical Trial
3 TrialsResearching Osteoporosis
25 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are willing to participate in 2x weekly exercise sessions.
You are 50 years of age or older.
You have received 2 vaccines for COVID-19.
Individuals at high risk of fracture (i.e., risk in next 10 years is >20% according to FRAX) should be offered medication for osteoporosis.
You are postmenopausal for at least 2 years.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References